Epilepsy
24 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Brain Diseases, Nervous System Diseases
Narrower: Drug Resistant Epilepsy 4, Epilepsies, Myoclonic 7, Epilepsies, Partial 3, Epilepsy, Absence 2, Epilepsy, Generalized 12, Lennox Gastaut Syndrome 1, Myoclonic Epilepsy, Juvenile 1, Spasms, Infantile 2
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 30mg PRAX-628 for epilepsy, generalized | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivaracetam for epilepsy, absence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cannabidiol for epilepsy, absence | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for lennox gastaut syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cenobamate (syrup) for 2 to < 18 year olds + Cenobamate (tablet) for 12 to < 18 year olds for epilepsies, partial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device: Directional Deep Brain Stimulation for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ETX101 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Exogenous ketone ester for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ION337 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JZP926 capsule for myoclonic epilepsy, juvenile | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| lentiviral gene therapy for drug resistant epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Opakalim for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Opakalim for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| RAP-219 for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relutrigine for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STK-001 - Single Ascending Doses for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zorevunersen for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.